Targeting LSD1 and FOXA1 in prostate cancer
FOXA1 is a key pioneer factor in androgen-receptor activity but has been an elusive drug target. A new study shows that inhibition of the associated cofactor LSD1 modifies the methylation state of FOXA1, thus resulting in chromatin dissociation and tumor inhibition, even in models of treatment-resis...
Saved in:
Published in | Nature genetics Vol. 52; no. 10; pp. 1002 - 1003 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
New York
Nature Publishing Group US
01.10.2020
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | FOXA1 is a key pioneer factor in androgen-receptor activity but has been an elusive drug target. A new study shows that inhibition of the associated cofactor LSD1 modifies the methylation state of FOXA1, thus resulting in chromatin dissociation and tumor inhibition, even in models of treatment-resistant prostate cancer. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Commentary-3 content type line 23 |
ISSN: | 1061-4036 1546-1718 |
DOI: | 10.1038/s41588-020-0702-6 |